BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liaw YF. Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol. 1997;12:S346-S353. [PMID: 9407357 DOI: 10.1111/j.1440-1746.1997.tb00520.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 You J, Cheng H, Yan S, Qiao Y, Huang J, Tang B, Wu G, Qu J, Wu R, Zhuang L, Ma Y. A Randomized, Controlled, Clinical Study of Thymosin Alpha-1 Versus Interferon-Alpha in Chinese Patients with Chronic Hepatitis B Lacking Hepatitis B Envelope Antigen. Journal of the Chinese Medical Association 2005;68:65-72. [DOI: 10.1016/s1726-4901(09)70137-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
2 Liaw YF. Chronic hepatitis B guidelines: east versus west. Hepatology. 2002;35:979-981. [PMID: 11915052 DOI: 10.1053/jhep.2002.32095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
3 Tsai FC, Hsieh SC, Chen DS, Sheu JC, Chen CH. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci. 2006;51:1627-1632. [PMID: 16927141 DOI: 10.1007/s10620-006-9074-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
4 Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol. 2003;18:246-252. [PMID: 12603523 DOI: 10.1046/j.1440-1746.2003.02976.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 112] [Article Influence: 5.9] [Reference Citation Analysis]
5 Kuo YH, Chen CH, Wang JH, Hung CH, Tseng PL, Lu SN, Changchien CS, Lee CM. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45:75-81. [PMID: 20030580 DOI: 10.3109/00365520903394550] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
6 Wu CH, Hsu TY, Kung FT, ChangChien CC, Tsai CC, Lu SN. Changes in the Prevalence of HBsAg and HBeAg: a Study of 8696 Parturients in a Well Vaccinated Area. Sci Rep 2017;7:1212. [PMID: 28450703 DOI: 10.1038/s41598-017-01234-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology. 2000;32:604-609. [PMID: 10960456 DOI: 10.1053/jhep.2000.9717] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 3.0] [Reference Citation Analysis]
8 García-contreras F, Nevárez-sida A, Constantino-casas P, Abud-bastida F, Garduño-espinosa J. Cost-effectiveness of Chronic Hepatitis C Treatment with Thymosin Alpha-1. Archives of Medical Research 2006;37:663-73. [DOI: 10.1016/j.arcmed.2005.11.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
9 Ferreira MS. Diagnóstico e tratamento da hepatite B. Rev Soc Bras Med Trop 2000;33:389-400. [DOI: 10.1590/s0037-86822000000400010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Peng CW, Jeng WJ, Chien RN, Liaw YF. The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B. J Viral Hepat 2021;28:475-83. [PMID: 33274536 DOI: 10.1111/jvh.13449] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Quinn DN, Pfeil SA. Gastroenterology. Clinics in Podiatric Medicine and Surgery 2002;19:23-42. [DOI: 10.1016/s0891-8422(03)00079-x] [Reference Citation Analysis]
12 Lau GK. Hepatitis B infection in China. Clin Liver Dis. 2001;5:361-379. [PMID: 11385968 DOI: 10.1016/s1089-3261(05)70170-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
13 Zhang JC, Nie QH. New antiviral choice for chronic hepatitis B: tenofovir disoproxil fumarate. Shijie Huaren Xiaohua Zazhi 2008; 16(24): 2679-2688 [DOI: 10.11569/wcjd.v16.i24.2679] [Reference Citation Analysis]
14 Kao J, Chen P, Lai M, Chen D. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004;72:363-9. [DOI: 10.1002/jmv.10534] [Cited by in Crossref: 123] [Cited by in F6Publishing: 127] [Article Influence: 6.8] [Reference Citation Analysis]
15 Liu J, Mcintosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B: a systematic review: Medicinal herbs for chronic hepatitis B. Liver 2001;21:280-6. [DOI: 10.1034/j.1600-0676.2001.021004280.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
16 Yeh C, Sheen I, Chen T, Hsieh S, Chu C, Liaw Y. Prednisolone modulates the therapeutic effect of interferon to eliminate preferentially the hepatitis B virus precore stop mutant. Journal of Hepatology 2000;32:829-36. [DOI: 10.1016/s0168-8278(00)80253-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Saruc M, Ozden N, Turkel N, Ayhan S, Hock LM, Tuzcuoglu I, Yuceyar H. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci. 2003;92:1386-1395. [PMID: 12820143 DOI: 10.1002/jps.10401] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
18 Sun Q, Liu ZH, Chen J, Ji S, Tang Z, Cheng Z, Ji D, Li LS. An aggressive systematic strategy for acute respiratory distress syndrome caused by severe pneumonia after renal transplantation. Transpl Int. 2006;19:110-116. [PMID: 16441359 DOI: 10.1111/j.1432-2277.2005.00245.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
19 Chu C. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15:E25-30. [DOI: 10.1046/j.1440-1746.2000.02097.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 108] [Article Influence: 5.3] [Reference Citation Analysis]
20 Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology. 1999;30:770-774. [PMID: 10462384 DOI: 10.1002/hep.510300313] [Cited by in Crossref: 175] [Cited by in F6Publishing: 162] [Article Influence: 7.6] [Reference Citation Analysis]
21 Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, Li AM, Shi MF, Zou L. Interruption of HBV intrauterine transmission: A clinical study. World J Gastroenterol 2003; 9(7): 1501-1503 [PMID: 12854150 DOI: 10.3748/wjg.v9.i7.1501] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 83] [Article Influence: 4.5] [Reference Citation Analysis]
22 Liaw YF. Treatment of chronic hepatitis B virus infection: who, when, what for and how. J Gastroenterol Hepatol 2000;15 Suppl:E31-3. [PMID: 10921379 DOI: 10.1046/j.1440-1746.2000.02099.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
23 Farrell GC. Immunosuppression and reactivation of hepatitis B in the lamivudine era: Opportunities for prevention and exploitation? Journal of Gastroenterology and Hepatology 1999;14:741-4. [DOI: 10.1046/j.1440-1746.1999.01962.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
24 Liaw YF. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. Hepatology. 2021;73:843-852. [PMID: 32810321 DOI: 10.1002/hep.31525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
25 Liu J, Zhu M, Shi R, Yang M. Radix Sophorae flavescentis for chronic hepatitis B: a systematic review of randomized trials. Am J Chin Med. 2003;31:337-354. [PMID: 12943166 DOI: 10.1142/S0192415X03001107] [Cited by in Crossref: 69] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
26 Lee WC, Wu MJ, Cheng CH, Chen CH, Shu KH, Lian JD. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001;38:1074-81. [PMID: 11684562 DOI: 10.1053/ajkd.2001.28607] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 2.2] [Reference Citation Analysis]
27 Pica F, Gaziano R, Casalinuovo IA, Moroni G, Buè C, Limongi D, D'Agostini C, Tomino C, Perricone R, Palamara AT, Sinibaldi Vallebona P, Garaci E. Serum thymosin alpha 1 levels in normal and pathological conditions. Expert Opin Biol Ther 2018;18:13-21. [PMID: 30063864 DOI: 10.1080/14712598.2018.1474197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat. 2002;9:393-399. [PMID: 12431200 DOI: 10.1046/j.1365-2893.2002.00388.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
29 Chu CM, Yeh CT, Lee CS, Sheen IS, Liaw YF. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol. 2002;40:16-21. [PMID: 11773086 DOI: 10.1128/jcm.40.1.16-21.2002] [Cited by in Crossref: 73] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
30 Miyano S, Togashi H, Shinzawa H, Sugahara K, Matsuo T, Takeda Y, Saito K, Saito T, Ishiyama S, Kaneko M. Case report: Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C. J Gastroenterol Hepatol. 1999;14:928-930. [PMID: 10535477 DOI: 10.1046/j.1440-1746.1999.01954.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 0.7] [Reference Citation Analysis]
31 Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol. 1998;13:14-20. [PMID: 9737566 DOI: 10.1111/j.1440-1746.1998.tb00539.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 2.2] [Reference Citation Analysis]
32 Lavanchy D. Public health measures in the control of viral hepatitis: a World Health Organization perspective for the next millennium. J Gastroenterol Hepatol 2002;17 Suppl:S452-9. [PMID: 12534777 DOI: 10.1046/j.1440-1746.17.s4.9.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
33 Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat. 2004;11:349-357. [PMID: 15230858 DOI: 10.1111/j.1365-2893.2004.00512.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
34 Zacharakis G, Koskinas J, Kotsiou S, Papoutselis M, Tzara F, Vafeiadis N, Archimandritis A, Papoutselis K. Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 2005;77:173-9. [DOI: 10.1002/jmv.20434] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 3.8] [Reference Citation Analysis]
35 Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39 Suppl 1:S50-S58. [PMID: 14708678 DOI: 10.1016/s0168-8278(03)00139-9] [Cited by in Crossref: 132] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
36 Liaw YF. Treatment of chronic hepatitis B: a need for consensus. J Gastroenterol Hepatol. 1999;14:1-2. [PMID: 10029270 DOI: 10.1046/j.1440-1746.1999.01813.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
37 Oon CJ. Prevention of human hepatocellular carcinoma with natural lymphoblastoid alpha interferon. J Gastroenterol Hepatol 2002;17 Suppl:S500-1. [PMID: 12534786 DOI: 10.1046/j.1440-1746.17.s4.18.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Liaw Y, Chien R. C ASE R EPORT: Dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B. Journal of Gastroenterology and Hepatology 1999;14:804-6. [DOI: 10.1046/j.1440-1746.1999.01960.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
39 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
40 Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971-975. [PMID: 10051505 DOI: 10.1002/hep.510290312] [Cited by in Crossref: 315] [Cited by in F6Publishing: 287] [Article Influence: 13.7] [Reference Citation Analysis]
41 Akuta N, Suzuki F, Tsubota A, Arase Y, Suzuki Y, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy. Dig Dis Sci 2002;47:405-14. [PMID: 11855559 DOI: 10.1023/a:1013742727165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Pramoolsinsup C. Management of viral hepatitis B. J Gastroenterol Hepatol. 2002;17 Suppl:S125-S145. [PMID: 12000599 DOI: 10.1046/j.1440-1746.17.s1.3.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.4] [Reference Citation Analysis]
43 Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, Tung HD, Chen TM, Changchien CS. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol. 2002;37:669-674. [PMID: 12399235 DOI: 10.1016/s0168-8278(02)00267-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
44 Liaw YF. Management of patients with chronic hepatitis B. J Gastroenterol Hepatol. 2002;17:406-408. [PMID: 11982720 DOI: 10.1046/j.1440-1746.2002.02736.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
45 Liu J, Lin H, McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hepat. 2001;8:358-366. [PMID: 11555193 DOI: 10.1046/j.1365-2893.2001.00307.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
46 . Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia–Pacific region 1: CORE WORKING PARTY FOR ASIA–PACIFIC CONSENSUS ONHEPATITIS B AND C 2. Journal of Gastroenterology and Hepatology 2001;15:825-39. [DOI: 10.1046/j.1440-1746.2000.02324.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 2.8] [Reference Citation Analysis]
47 Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol. 2014;61:1407-1417. [PMID: 25178562 DOI: 10.1016/j.jhep.2014.08.033] [Cited by in Crossref: 147] [Cited by in F6Publishing: 136] [Article Influence: 18.4] [Reference Citation Analysis]
48 Lau G, Carman W, Locarnini S, Okuda K, Lu Z, Williams R, Lam S. Treatment of chronic hepatitis B virus infection: An Asia–Pacific perspective. Journal of Gastroenterology and Hepatology 2002;14:3-12. [DOI: 10.1046/j.1440-1746.1999.01812.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
49 Gao Y, Gao H, Chan E, Tang W, Li X, Liang J, Zhou S. Protective Effect of Ganoderma (a Mushroom with Medicinal Properties) Against Various Liver Injuries. Food Reviews International 2005;21:27-52. [DOI: 10.1081/fri-200040586] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
50 Befeler AS, Di Bisceglie AM. Hepatitis B. Infect Dis Clin North Am. 2000;14:617-632. [PMID: 10987113 DOI: 10.1016/s0891-5520(05)70124-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]